Page 81 - Read Online

Author Instructions

OAE requires all authors to register all relevant clinical trials that are reported in manuscripts submitted. OAE follows the
World Health Organization (WHO)’s definition of clinical trials: “A clinical trial is any research study that prospectively
assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on
health outcomes. Interventions include but are not restricted to drugs, cells, other biological products, surgical procedures,
radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc.”.
In line with International Committee of Medical Journal Editors(ICMJE) recommendation, OAE requires the registration
of clinical trials in a public trial registry at or before the time of first patient enrollment. OAE accepts publicly accessible
registration in any registry that is a primary register of the WHO International Clinical Trials Registry Platform or in
ClinicalTrials.gov. The trial registration number should be listed at the end of the Abstract section.
Secondary data analyses of primary (parent) clinical trials should not be registered as a new clinical trial, but rather
reference the trial registration number of the primary trial.
Editors of OAE journals will consider carefully whether studies failed to register or had an incomplete trial registration.
Because of the importance of prospective trial registration, if there is an exception to this policy, trials must be registered
and the authors should indicate in the publication when registration was completed and why it was delayed. Editors will
publish a statement indicating why an exception was allowed. Please note such exceptions should be rare, and authors
failing to prospectively register a trial risk its inadmissibility to OAE journals.
Authors who are not sure whether they need trial registration may refer to ICMJE FAQs for further information.

3.2 Research Involving Animals
Experimental research on animals should be approved by an appropriate ethics committee and must comply with
institutional, national, or international guidelines. OAE encourages authors to comply with the AALAS Guidelines,
the ARRIVE Guidelines, and/or the ICLAS Guidelines, and obtain prior approval from the relevant ethics committee.
Manuscripts must include a statement indicating that the study has been approved by the relevant ethical committee and the
whole research process complies with ethical guidelines. If a study is granted an exemption from requiring ethics approval,
the name of the ethics committee granting the exemption and the reason(s) for the exemption should be detailed. Editors
will take account of animal welfare issues and reserve the right to reject a manuscript, especially if the research involves
protocols that are inconsistent with commonly accepted norms of animal research.

3.3 Research Involving Cell Lines
Authors must describe what cell lines are used and their origin so that the research can be reproduced. For established cell
lines, the provenance should be stated and references must also be given to either a published paper or to a commercial
source. For de novo cell lines derived from human tissue, appropriate approval from an institutional review board or
equivalent ethical committee, and consent from the donor or next of kin, should be obtained. Such statements should be
listed on the Declaration section of Ethical Approval and Consent to Participate in the manuscript.
Further information is available from theInternational Cell Line Authentication Committee (ICLAC). OAE recommends
that authors check the NCBI database for misidentification and contamination of human cell lines.

3.4 Publication Ethics Statement
OAE is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best
Practice Guidelines.
The Editors of this journal enforce a rigorous peer-review process together with strict ethical policies and standards to
guarantee to add high-quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data
falsification, image manipulation, inappropriate authorship credit, and the like, do arise. The Editors of Metabolism and
Target Organ Damage take such publishing ethics issues very seriously and are trained to proceed in such cases with zero
tolerance policy.
Authors wishing to publish their papers in Metabolism and Target Organ Damage must abide to the following:
The author(s) must disclose any possibility of a conflict of interest in the paper prior to submission.
The authors should declare that there is no academic misconduct in their manuscript in the cover letter.
Authors should accurately present their research findings and include an objective discussion of the significance of their
findings.
Data and methods used in the research need to be presented in sufficient detail in the manuscript so that other researchers
can replicate the work.
Authors should provide raw data if referees and the Editors of the journal request.
Simultaneous submission of manuscripts to more than one journal is not tolerated.
Republishing content that is not novel is not tolerated (for example, an English translation of a paper that is already published
in another language will not be accepted).
The manuscript should not contain any information that has already been published. If you include already published
figures or images, please get the necessary permission from the copyright holder to publish under the CC-BY license.
Plagiarism, data fabrication and image manipulation are not tolerated.
Plagiarism is not acceptable in OAE journals.

XI Metabolism and Target Organ Damage